Marina Biotech said this week that the Canadian patent office has issued the company a notice of allowance for a patent application covering amphoteric liposomal formulations and their use for the delivery of nucleic acids and other compounds with therapeutic application.
The application, No. 2,438,116, specifically relates to Marina's Smarticles technology, which it acquired from Novosom last summer (GSN 7/29/2010).